Zealand Pharma Shares Plunge 12% on Obesity Drug Trial Side Effects

Key Facts

Zealand Pharma shares fell 12% on October 1, 2026. Investing.com reported that the decline followed the emergence of side effects in trials for the company's obesity drug, raising concerns regarding the treatment's safety profile.

The release of clinical trial data triggered a negative market reaction as investor confidence in the candidate drug's competitive viability weakened. The stock maintained a downward direction during trading on October 1, 2026, as the market assessed the impact of these setbacks on the firm's position in the obesity drug sector.